|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors : Determination of a pharmacokinetic/pharmacodynamic relationship 显示文摘 | Medel DB Laird AD Xin X | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 2 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetid pharmacodynamic relationship显示文摘 | Mendel DB laird AD Xin X | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 3 | Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248显示文摘 | Potapova O Laird AD Nannini MA | 2006 | Mol Cancer Ther2006，5，5： | 1 |
| 4 | SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors显示文摘 | Laird AD Vajkoczy P Shawver LK | 2000 | Cancer Res2000，60，15： | 1 |
| 5 | SU6668 Inhibits Flk-1/KDR and PDGFRbeta in Vivo, Resulting in Rapid Apoptosis of Tumor Vasculature and Tumor Regression in Mice显示文摘 | LAIRD AD CHRISTENSEN JG LI G | 2002 | FASEB J2002，16，7： | 1 |
| 6 | Charac terization of Raf-1 activation in mitosis 显示文摘 | MORRISON DK Shalloway D | 1999 | J Biol Chem1999，274，7： | 1 |
| 7 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship 显示文摘 | Mendel DB Laird AD Xin X | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 8 | In vivo antitu-mor activity of SU11248,a novel tyrosine kinase in-hibitor targeting vascular endothelial growth factor andplatelet-derived growth factor receptors显示文摘 | Mendell BD Laird AD Xin XH | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 9 | Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248显示文摘 | Potapova O Laird AD Nannini MA | 2006 | Mol Cancer Ther2006，5，5： | 1 |
| 10 | Dynamics of normal growth 显示文摘 | laird AK Tyler SA Barton AD | 1965 | Growth1965，29，3： | 1 |
| 11 | Effects of cavi- tational activity on the root surface of teeth during ultrasonic scaling显示文摘 | Walmsley AD Walsh TF Laird WR | 1990 | J Clin Periodontol1990，17，5： | 1 |
| 12 | SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors显示文摘 | LAIRD AD Vajkoczy P Shawver LK | | 0，，： | 1 |
| 13 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship显示文摘 | Mendel DB Laird AD Xin X | 2003 | Clin Cancer Res2003，9，： | 1 |
| 14 | Contribu- tion of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SUl1248显示文摘 | Potapova O Laird AD Nannini MA | 2006 | Mol Cancer Ther2006，5，5： | 1 |
| 15 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship 显示文摘 | Mendel DB Laird AD Xin X | 2003 | Clin Cancer Res2003，9，3： | 1 |
| 16 | Development of SU5416, a selective small molecule inhibits of VEGF receptor tyrosine kirase activity, as an anti-angiogenesis agent显示文摘 | Mendel DB Laird AD Smolich BD | 2000 | AntiCancer Drug Design2000，15，1： | 1 |
| 17 | Effects of cavitational activity on the root surface of teeth during ultrasonic sealing显示文摘 | Walmsley AD Walsh TF Laird WR | 1990 | J Clin Periodontol1990，17，5： | 1 |
| 18 | Development of Su5416 a selective Small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an angiogenesis agent显示文摘 | Mendel DB Laird AD Smolich BD | 2000 | J Anticancer Drug Des2000，15，1： | 1 |
| 19 | In vivo antitu- mor activity of SU11248, a novel tyrosine kinase inhib- itor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship 显示文摘 | Mendel DB Laird AD Xin X | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 20 | SU6668 is a potent antiangiogenic and antitumor agent that induces regression of astablished tumors 显示文摘 | Laird AD Vajkoczy P Shawver LK | 2000 | Cancer Res2000，60，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员